• Pfizer raised its 2026 revenue forecast to $62 billion to $64 billion from $60.5 billion to $62.5 billion.
• Adjusted diluted earnings guidance increased to $2.95 to $3.05 per share from $2.80 to $3.00.
• Projected adjusted R&D spending rose to $10.8 billion to $11.8 billion from $10.5 billion to $11.5 billion.
• Third-quarter revenue totaled $16.6 billion, roughly flat year over year; adjusted diluted earnings were $0.87 per share.
• Non-COVID revenue grew 7% operationally, offset by declines in COVID treatments, vaccines and other products.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.